Company Overview

CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease.

A Powerful Approach

While traditional drug discovery has focused on drugs that target a single biological pathway to treat disease, CombinatoRx is working from the scientific understanding that most diseases affect the body through multiple pathways. CombinatoRx creates synergistic combination drug candidates that simultaneously attack disease on multiple fronts. This approach transcends the separate mechanisms of the individual drug components by treating diseases through entirely new mechanisms of action enabled by the synergies of our combinations.

Creating Drug Candidates with Novel Mechanisms

By targeting multiple physiologic pathways and hitting multiple targets within the body, we can elucidate novel ways to better treat a wide variety of serious diseases with:

• Strong selective activity against the disease network
• Wider therapeutic window to create potentially safer and more active pharmaceuticals
• Established pharmacological and toxicology profiles
• Rapid progression to phase 2 proof-of-concept human clinical trials

Broad Portfolio in Clinical Development

The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2 proof-of-concept results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates.

CombinatoRx Products